Daniel Chung
Company: SparingVision
Job title: Chief Medical Officer
Bio:
Dr. Chung is a trained ophthalmologist who has been instrumental in the development of genetic ocular therapies for blinding diseases for almost 30 years, in the academic (UPenn) and industry (Spark Tx) spaces. He was heavily involved in the developmentĀ of voretigene neparvovec, the first FDA approved gene therapy for a genetic eye disease. Currently, in a CMO role for SparingVision, developing gene independent approaches to save vision in patients with inherited retinal disease.
Seminars:
INNOVATIVE TRIAL DESIGN TO GENERATE CLINICAL DATA 1:00 pm
Understanding the pain points of running clinical trials with rare and ultrarare populations Highlighting creative clinical trial design approaches and their potential benefits over conventional approaches for trials with small patient numbers Presenting case studies on innovation in trial design Practical advice for setting and analyzing multiple endpoints in a clinical trial Calibrating trial design…Read more
day: Workshop Day - track b PM
Outlining How to Establish & Run an Effective Natural History Study 1:45 pm
How to effectively incorporate multiple stakeholder perspectives when planning and designing natural history data collection efforts Challenges faced and solutions implemented in running a natural history study Top tips for maximizing the use of natural history data in clinical trial design and outcome assessmentsRead more
day: Day 2 CLINICAL PM
Panel Discussion: Unpicking the Complexities of External Control Arms 12:00 pm
Identifying the challenges associated with conductingĀ robust external control arm studies in small, heterogenousĀ patient cohort Methodological considerations for using external controlĀ arms to credibly demonstrate the effectiveness of a rareĀ gene therapy Key lessons learned from clinical trial designsĀ incorporating external controls Considerations for using natural history studies as externalĀ control armsRead more
day: Clinical - AM